Comparative Pharmacology
Head-to-head clinical analysis: ANHYDRON versus BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANHYDRON versus BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE.
ANHYDRON vs BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Bisoprolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate and myocardial contractility, decreasing cardiac output. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
One tablet orally once daily. Initial dose: 2.5 mg/6.25 mg to 10 mg/25 mg, titrated based on response. Maximum: 20 mg/50 mg per day.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Bisoprolol: terminal half-life 10-12 hours (up to 15 hours in elderly/clinically significant for once-daily dosing); Hydrochlorothiazide: terminal half-life 6-15 hours (prolonged in renal impairment).
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Bisoprolol: 50% unchanged in urine, remainder as inactive metabolites; Hydrochlorothiazide: 95% unchanged in urine. Fecal elimination: negligible.
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic